Know Cancer

or
forgot password


Phase 3
18 Years
60 Years
Open (Enrolling)
Both
Hodgkins Lymphoma

Thank you

Trial Information


Inclusion Criteria:



- Hodgkin Lymphoma (histologically proven)

- CS (PS) IIB with one or both of the risk factors:

- bulky mediastinal mass (> 1/3 of maximum transverse thorax diameter)

- extranodal involvement

- CS (PS) III, IV

- Written informed consent

Exclusion Criteria:

- Leucocytes < 3000/µl

- Platelets < 100000/µl

- Hodgkin´s lymphoma as "composite lymphoma"

- Activity index (WHO) < grade 2

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression Free Survival

Outcome Time Frame:

5 years

Safety Issue:

No

Principal Investigator

Andreas Engert, Prof.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Cologne

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

HD18

NCT ID:

NCT00515554

Start Date:

May 2008

Completion Date:

Related Keywords:

  • Hodgkins Lymphoma
  • Hodgkin lymphoma
  • PET
  • advances stages
  • Rituximab
  • Hodgkin Disease
  • Lymphoma

Name

Location